Balyasny Asset Management LLC Vir Biotechnology, Inc. Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

A detailed history of Balyasny Asset Management LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 26,433 shares of VIR stock, worth $195,604. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,433
Holding current value
$195,604
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$7.26 - $10.7 $191,903 - $282,833
26,433 New
26,433 $197,000
Q3 2023

Nov 14, 2023
SELL
$9.14 - $24.62 $2.59 Million - $6.97 Million
-283,248 Reduced 54.59%
235,604 $2.21 Million
Q2 2023

Aug 14, 2023
BUY
$23.2 - $27.29 $2.69 Million - $3.16 Million
115,904 Added 28.76%
518,852 $12.7 Million
Q1 2023

May 15, 2023
BUY
$22.26 - $30.85 $8.97 Million - $12.4 Million
402,948 New
402,948 $9.38 Million
Q3 2022

Nov 14, 2022
BUY
$18.26 - $31.1 $6.85 Million - $11.7 Million
374,897 Added 3657.89%
385,146 $7.43 Million
Q2 2022

Aug 15, 2022
BUY
$19.08 - $26.7 $195,550 - $273,648
10,249 New
10,249 $261,000
Q1 2022

May 16, 2022
SELL
$21.19 - $40.01 $4.63 Million - $8.75 Million
-218,710 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$30.97 - $54.03 $5.94 Million - $10.4 Million
191,899 Added 715.75%
218,710 $9.16 Million
Q3 2021

Nov 15, 2021
BUY
$34.9 - $54.54 $260,633 - $407,304
7,468 Added 38.61%
26,811 $1.17 Million
Q2 2021

Aug 16, 2021
BUY
$38.75 - $51.0 $749,541 - $986,493
19,343 New
19,343 $915,000
Q2 2020

Aug 14, 2020
SELL
$27.89 - $47.86 $2.57 Million - $4.4 Million
-91,977 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$12.04 - $60.2 $1.11 Million - $5.54 Million
91,977 New
91,977 $3.15 Million

Others Institutions Holding VIR

# of Institutions
218
Shares Held
87M
Call Options Held
127K
Put Options Held
1.19M
View Full List

About Vir Biotechnology, Inc.

VIR Quotes by TradingView
  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $982M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email